NCT00396786 - Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement | Biotech Hunter

Enrollment

877

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

July 31, 2005

Study Completion Date

July 31, 2005

Conditions

Venous Thromboembolism

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Rivaroxaban 5 mg once daily plus placebo enoxaparin syringe

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Rivaroxaban 10 mg once daily plus placebo enoxaparin syringe

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Rivaroxaban 20 mg once daily plus placebo enoxaparin syringe

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Rivaroxaban 30 mg once daily plus placebo enoxaparin syringe

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Rivaroxaban 40 mg once daily plus placebo enoxaparin syringe

DRUG

Enoxaparin

Enoxaparin 40 mg once daily plus Rivaroxaban placebo tablets

Trial Locations (62)

1220

Vienna

2020

Antwerp

2700

Wiener Neustadt

2730

Herlev

2820

Bonheiden

2900

Hellerup

3500

Hasselt

3600

Genk

4010

Linz

4020

Linz

8600

Silkeborg

16766

Sommerfeld

20052

Monza

20089

Rozzano

20122

Milan

20132

Milan

28040

Madrid

31096

Haifa

34212

Melsungen

35043

Marburg

40136

Bologna

40225

Düsseldorf

44281

Kfar Saba

44819

Saint-Herblain

46010

Valencia

49100

Petah Tikva

49372

Petah Tikva

58100

Holon

60528

Frankfurt am Main

64239

Tel Aviv

65929

Frankfurt am Main

70300

Ẕerifin

75019

Paris

75877

Paris

79618

Rheinfelden

82467

Garmisch-Partenkirchen

86000

Poitiers

90766

Fürth

DK-2970

Hørsholm

01307

Dresden

06024

Gubbio

1213 XZ

Hilversum

2134 TM

Hoofddorp

6522 JV

Nijmegen

NO-3675

Notodden

0440

Oslo

NO-3660

Rjukan

15-276

Bialystok

80-742

Gdansk

31-826

Krakow

20-090

Lublin

20-718

Lublin

00-909

Warsaw

08916

Badalona

08035

Barcelona

08036

Barcelona

416 85

Gothenburg

301 85

Halmstad

551 85

Jönköping

442 83

Kungälv

SE5 9RS

London

W6 0TN

London